Emily Slotkin

MSK Kids, Pediatric Sarcoma Service | DSRCT, Ewing and other AYA sarcomas | Memorial Sloan Kettering Cancer Center

[Michael Ortiz @MichaelVOrtiz]

Here we provide an update on high risk Wilms tumors as a part of the @COGorg and @WorldSIOP pediatric renal tumor collaborative #HARMONICA initiative - https://t.co/dlbNBWdgzR

[Michael Ortiz @MichaelVOrtiz]

Robust translational partnerships are essential to rapidly advance novel therapies for #childhoodcancer; herein @HeathcliffDora1 @anton_gh find ATRi as a novel approach to treat #ARMS which directly informed the actively recruiting @COGorg study PEPN2112 https://t.co/rgEGrlGAb8

[Emily Slotkin @EmilySlotkin]

@WCMEnglanderIPM @MSKCancerCenter @WCMC_CTSC Thank you @WCMC_CTSC!

[Emily Slotkin @EmilySlotkin]

@WCMEnglanderIPM @MSKCancerCenter @WCMC_CTSC Thank you @WCMC_CTSC!

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

🔬TODAY "How Osteosarcoma Evolves from Diagnosis to Relapse" - @MDKinnz of @MSKCancerCenter is joining us on OsteoBites to talk about this evolution.

👉You can join us LIVE today, Thursday at 3pm EDT:
https://t.co/iacT9RnK34

✨This episode is sponsored by @osinstitute (OSI)

[The Lancet @TheLancet]

"An intercontinental divide for the upfront treatment of Ewing sarcoma has persisted... The EE2012 results harmonise treatment approaches."

@EmilySlotkin & @WTapMD provide a linked Comment: https://t.co/WtaumEicf3

[ACCELERATE @ACCELERATE_cure]

📢The 10th Paediatric Strategy Forum for DNA Damage Repair Pathway Inhibitors has now begun at @EMA_News!

➡️Stay tuned for the summary and manuscript addressing the challenges and documenting the conclusions of the meeting.

#ChildhoodCancer #DrugDevelopment #ACCELERATEcure

[MSK Library @MSKLibrary]

Featured today by @MSKLibrary: Leveraging Circulating Tumor DNA to Optimize the Initial Management of Childhood #RenalTumors @MichaelVOrtiz @JCO_ASCO
https://t.co/G4i7Liy69e

[Anton Henssen @anton_gh]

Very happy to share this new publication from our lab, led by @HeathcliffDora1 , where we describe that preclinical models of alveolar rhabdomysarcoma are exceptionally sensitive to pharmacological ATR inhibition 🔥🔥👇🏻👇🏻 @NatureComms #1
https://t.co/9gC5YRaSVp

[Michael Kinnaman, MD MS @MDKinnz]

Had a blast this morning sharing a snapshot of my work studying clonal evolution in osteosarcoma! Work made possible by the support of many generous foundations including @ConquerCancerFd @hopeonwheels @quadwfoundation @RallyFoundation.
Hoping to share the full story soon!#ASCO22

[Emily Slotkin @EmilySlotkin]

@bvantine1 Congratulations Brian!

[Emily Slotkin @EmilySlotkin]

Many thanks to all collaborators for their work on and attention to #DSRCT! @MLadanyi @ahmetz @PapaemmanuilLab @WTapMD @MCR_AACR @sloan_kettering

[Molecular Cancer Research @MCR_AACR]

Desmoplastic Small Round Cell Tumor is defined by a simple and balanced translocation and characterized by a paucity of recurrent mutations. FGFR4 overexpression may represent a therapeutic vulnerability. https://t.co/9N3FKXSCt7 #DSRCT

[Emily Slotkin @EmilySlotkin]

👏most fun…👏birthday present…👏ever! thank you mom, mattie and @dglaucomflecken 🤩
https://t.co/iFHu8R3zPl

[Emily Slotkin @EmilySlotkin]

@padocabakery thank goodness! can’t wait...

[NY Genome Center @nygenome]

Join us for the VIRTUAL Very Rare Cancer Consortium Disease Spotlight & Research Roundtable on #DSCRT, 3/18, 4pm – 6pm. Speakers from @sloan_kettering (including @EmilySlotkin, @MLadanyi, @oleg8r, & @906Madelyn) plus @columbia & @MDAndersonNews. Details: https://t.co/kFSCfNzdS6

[Dear Dr. Researcher, PhD @corrie_painter]

It would mean a great deal to me if everyone I know, & everyone you know would RT this post about our genomics cancer projects. Anyone dx'd with a brain tumor or osteosarcoma in the US & Canada can join here: https://t.co/cPi4T8dnkX & https://t.co/Vww0mc4IzE #BTSM #Sarcoma TY!

[Emily Slotkin @EmilySlotkin]

@sugarpond gets to the heart of the matter: https://t.co/BGa2bj5kDJ @WNYC

[Emily Slotkin @EmilySlotkin]

congratulations to @MLadanyi @lee_spraggon and all others on this paper! clinical trial based on these data evaluating TPX-005 with irinotecan/temozolomide in relapsed/refractory DSRCT will be open in ~2 months @sloan_kettering led by the amazing Dr. Tara O’Donohue #DSRCT

[Emily Slotkin @EmilySlotkin]

@bvantine1 @MLadanyi the clinical trial is undergoing approvals and will be open @sloan_kettering in ~2 months led by dynamo Dr. Tara O’Donohue; will be TPX-005 + irinotecan/temozolomide with a specific cohort for relapsed/refractory #DSRCT patients based on these data...eager to get started!

[Emily Slotkin @EmilySlotkin]

@VivekSubbiah @MLadanyi the clinical trial is undergoing approvals and will be open @sloan_kettering in ~2 months led by dynamo Dr. Tara O’Donohue; will be TPX-005 + irinotecan/temozolomide with a specific cohort for relapsed/refractory #DSRCT patients based on these data...eager to get started!